We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Survey on Hypertension (SERENITE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00804167
First Posted: December 8, 2008
Last Update Posted: July 21, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Condition
Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage [ Time Frame: once ]

Estimated Enrollment: 4500
Study Start Date: December 2008
Study Completion Date: July 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   75 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The first 3 consecutive patients seen during the GP's visit with a diagnosis of Hypertension and with renal damage
Criteria

Inclusion Criteria:

  • Male or female aged 75 years or older
  • With a diagnosis of Hypertension treated or not, seen in general practitioner consultation
  • Who has given his/her consent to participate to the study.

Exclusion Criteria:

  • Patient who participated to a clinical trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00804167


  Show 1300 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00804167     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2008/1
First Submitted: December 5, 2008
First Posted: December 8, 2008
Last Update Posted: July 21, 2009
Last Verified: July 2009

Keywords provided by AstraZeneca:
Hypertensive patients aged of 75 years and older
renal damage
Clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases